MINDRANK AI CEO OUTLINES STRATEGY FOR AI DRUG DISCOVERY

The biotech executive discussed how AI is reshaping drug discovery processes, a sector traditionally dominated by lengthy development timelines and high failure rates. Mindrank AI focuses on leveraging machine learning to accelerate identification of drug candidates and streamline clinical research pathways. Zhangming addressed the company's positioning within Asia's growing biotech ecosystem, highlighting opportunities in cross-border innovation and technology transfer. The discussion covered both technical applications and market expansion strategies as AI biotech firms increasingly attract investment across the region. Mindrank AI operates at the intersection of artificial intelligence and pharmaceutical research, areas gaining significant traction among venture investors and established biotech companies seeking competitive advantages in drug development efficiency.